Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.44 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.43 |
| ▸ | GCGR | P47871 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | GSK3A | P49840 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24428623 | 0.86 | PIM1 (0.50) | ACHEPTGS2PTGS1NFE2L2MAOB | |
| SCHEMBL24766983 | 0.86 | CA3 (0.44) | PTGS2PTGS1NFE2L2MAOBRPS6KA3 | |
| SCHEMBL29892794 | 0.84 | PTGS2 (0.47) | ACHEPTGS2PTGS1NFE2L2PIM1 | |
| SCHEMBL10094630 | 0.83 | ACHE (0.50) | ACHEPTGS2PTGS1NFE2L2GCGR | |
| SCHEMBL1046583 | 0.83 | ACHE (0.50) | ACHEPTGS2PTGS1NFE2L2GCGR | |
| SCHEMBL12011032 | 0.81 | PTGS2 (0.57) | ACHEPTGS2PTGS1NFE2L2GCGR | |
| SCHEMBL7870739 | 0.81 | PTGS2 (0.44) | PTGS2PTGS1NFE2L2PIM1SRC | |
| SCHEMBL17110104 | 0.81 | ACHE (0.48) | ACHEPTGS2PTGS1NFE2L2GCGR | |
| SCHEMBL10304724 | 0.79 | PTGS2 (0.47) | PTGS2PTGS1 | |
| SCHEMBL22294759 | 0.79 | PTGS2 (0.43) | ACHEPTGS2PTGS1NFE2L2GCGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4209491-A1 | ENANTIOMERS OF SUBSTITUTED THIAZOLES AS ANTIVIRAL COMPOUNDS | Innovative Molecules GmbH (DE) | 2023-07-12 | — | — | EP | disclosed |
| EP-3692039-B1 | ENANTIOMERS OF SUBSTITUTED THIAZOLES AS ANTIVIRAL COMPOUNDS | INNOVATIVE MOLECULES GMBH (DE) | 2022-12-14 | — | — | EP | disclosed |
| US-20220152008-A1 | Enantiomers Of Substituted Thiazoles As Antiviral Compounds | INNOVATIVE MOLECULES GMBH (DE) | 2022-05-19 | — | — | US | disclosed |
| EP-3440063-B1 | AMINOTHIAZOLE DERIVATIVES USEFUL AS ANTIVIRAL AGENTS | INNOVATIVE MOLECULES GMBH (DE) | 2020-08-05 | — | — | EP | disclosed |
| US-10590094-B2 | Aminothiazole derivatives useful as antiviral agents | INNOVATIVE MOLECULES GMBH (DE) | 2020-03-17 | — | — | US | disclosed |
| US-20190112285-A1 | Aminothiazole Derivatives Useful As Antiviral Agents | INNOVATIVE MOLECULES GMBH (DE) | 2019-04-18 | — | — | US | disclosed |
| WO-2019068817-A1 | ENANTIOMERS OF SUBSTITUTED THIAZOLES AS ANTIVIRAL COMPOUNDS | INNOVATIVE MOLECULES GMBH (DE) | 2019-04-11 | — | — | WO | disclosed |
| US-20170333406-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-23 | — | — | US | disclosed |
| US-9763922-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| WO-2016086200-A9 | 4,5,6,7-TETRAHYDRO-1 H-PYRAZOLO[4,3-C]PYRIDIN-3-AMINE COMPOUNDS AS CBP AND/OR EP300 INHIBITORS | GENENTECH, INC. (US) | 2016-06-23 | — | — | WO | disclosed |
| US-8987304-B2 | Antituberculous composition comprising oxazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-03-24 | — | — | US | disclosed |
| US-8952207-B2 | Copper-catalyzed C—H bond arylation | THE UNIVERSITY OF HOUSTON SYSTEM (US) | 2015-02-10 | — | — | US | disclosed |
| US-8952207-B2 | Copper-catalyzed C—H bond arylation | THE UNIVERSITY OF HOUSTON SYSTEM (US) | 2015-02-10 | — | — | US | disclosed |
| US-8952207-B2 | Copper-catalyzed C—H bond arylation | THE UNIVERSITY OF HOUSTON SYSTEM (US) | 2015-02-10 | — | — | US | disclosed |
| EP-2269694-A2 | Antituberculous composition comprising oxazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-01-05 | — | — | EP | disclosed |
| US-20090275528-A1 | ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-11-05 | — | — | US | disclosed |
| US-20090076266-A1 | COPPER-CATALYZED C-H BOND ARYLATION | THE UNIVERSITY OF HOUSTON SYSTEM (US) | 2009-03-19 | — | — | US | disclosed |
| US-20090076266-A1 | COPPER-CATALYZED C-H BOND ARYLATION | THE UNIVERSITY OF HOUSTON SYSTEM (US) | 2009-03-19 | — | — | US | disclosed |
| US-20090076266-A1 | COPPER-CATALYZED C-H BOND ARYLATION | THE UNIVERSITY OF HOUSTON SYSTEM (US) | 2009-03-19 | — | — | US | disclosed |
| WO-2003061652-A1 | 3-(IMIDAZOLYL)-2-ALKOXYPROPANOIC ACIDS AS TAFIA INHIBITORS | PFIZER LIMITED (GB) | 2003-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170333406-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | EP300, HDAC1, HDAC10 | ACHE 4103/4885PTGS2 2857/4885PTGS1 2097/4885 |
| US-20190112285-A1 | Aminothiazole Derivatives Useful As Antiviral Agents | MAVS, EIF2AK2, SARS1 | ACHE 4641/4885PTGS2 2691/4885PTGS1 2031/4885 |
| US-20220152008-A1 | Enantiomers Of Substituted Thiazoles As Antiviral Compounds | EIF2AK2, MAVS, ZC3HAV1 | ACHE 4546/4885PTGS2 3182/4885PTGS1 2976/4885 |
| US-20090275528-A1 | ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS | OXA1L, ARG1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | ACHE 2191/4885PTGS2 2713/4885PTGS1 1542/4885 |
| US-20090076266-A1 | COPPER-CATALYZED C-H BOND ARYLATION | AOC2, AOC3, DBH | ACHE 3552/4885PTGS2 2323/4885PTGS1 2445/4885 |
| US-10590094-B2 | Aminothiazole derivatives useful as antiviral agents | MAVS, EIF2AK2, SARS1 | ACHE 4641/4885PTGS2 2691/4885PTGS1 2031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.